Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,521,340 papers from all fields of science
Search
Sign In
Create Free Account
IPH2201
Known as:
IPH-2201
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Monalizumab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.
N. Segal
,
J. Naidoo
,
+11 authors
J. Diamond
2018
Corpus ID: 81344140
3540Background: Monalizumab (IPH2201) is a humanized IgG4 antibody targeting CD94/NKG2a to suppress inhibitory signaling by…
Expand
2018
2018
Abstract 1690: NKG2A immune checkpoint blockade potentiates cetuximab induced ADCC in head and neck cancer preclinical model
C. Soulas
,
A. Lalanne
,
+9 authors
P. André
Immunology
2018
Corpus ID: 81802946
Monalizumab (IPH2201) is a first-in-class humanized IgG4 targeting NKG2A (Natural Killer Group 2A), which is expressed as a…
Expand
2017
2017
Abstract 5666: Safety of the first-in-class anti-NKG2A monoclonal antibody monalizumab in combination with cetuximab: a phase Ib/II study in recurrent or metastatic squamous cell carcinoma of the…
R. Cohen
,
S. Salas
,
+8 authors
J. Fayette
2017
Corpus ID: 79955659
Background: Monalizumab (IPH2201) is a first-in-class immune checkpoint inhibitor targeting CD94-NKG2A receptors expressed on…
Expand
2016
2016
Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221
A. Tinker
,
H. Hirte
,
+8 authors
L. Seymour
2016
Corpus ID: 78339461
2016
2016
Abstract 2342: NKG2A immune checkpoint blockade enhances the anti-tumor efficacy of PD1/PD-L1 inhibitors in a preclinical model
C. Sola
,
T. Arnoux
,
+8 authors
P. André
2016
Corpus ID: 78104100
Monalizumab (IPH2201) is a novel, first-in-class humanized IgG4 targeting the immune checkpoint receptor NKG2A (Natural Killer…
Expand
2015
2015
O3.2Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A
L. Seymour
,
A. Tinker
,
H. Hirte
,
N. Wagtmann
,
P. Dodion
2015
Corpus ID: 71489362
ABSTRACT There has been a recent resurgence of interest in immunotherapy, particularly in the domain of immune checkpoint…
Expand
2015
2015
Immuno-oncology moves beyond PD-1
C. Sheridan
Nature Biotechnology
2015
Corpus ID: 2498318
673 Ugur Sahin, CEO of Mainz, Germany–based BioNTech. “We believe there’s ample evidence macrophages can create an…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE